GPER may also be implicated in the processes of decreased sensitivity or resistance to tamoxifen in ER-positive and GPER-positive breast cancer because tamoxifen is known to cause a GPER-mediated proliferative effect in breast cancer cells [6], [7]. Here, ESR1 is linked to breast carcinoma.